Cardiac Amyloidosis: The Protein Deposit Disease That Stiffens the Heart
The heart is one of the most resilient organs in the human body. Yet certain diseases attack it silently, leaving little warning until serious damage has already occurred. Cardiac amyloidosis is one such condition — a disease where abnormal proteins accumulate inside the heart walls, gradually robbing them of flexibility and function.
This condition affects tens of thousands of people worldwide, yet it remains widely underdiagnosed. Many patients live with symptoms for years before receiving an accurate diagnosis. Understanding this disease is the first step toward earlier detection and better outcomes.
What Is Cardiac Amyloidosis?
Cardiac amyloidosis occurs when misfolded proteins clump together and deposit inside the heart muscle. These deposits, called amyloid fibrils, are abnormally shaped and cannot be broken down by the body. Over time, they build up within the heart walls, making the muscle thick and stiff.
A stiff heart cannot fill with blood properly between beats. This impairs the heart’s ability to pump blood to the rest of the body efficiently. The result is a condition called restrictive cardiomyopathy, which leads to heart failure if left untreated.
How Amyloid Proteins Form
Proteins in the body normally fold into precise three-dimensional shapes to perform specific functions. In amyloidosis, certain proteins misfold and aggregate into insoluble fibrils. These fibrils deposit in tissues and organs, causing progressive structural damage.
The heart is particularly vulnerable because it is a highly active muscle that continuously contracts. Once amyloid infiltrates the cardiac tissue, the damage is cumulative and difficult to reverse.
Types of Cardiac Amyloidosis
Not all cardiac amyloidosis is the same. The disease is classified based on the type of protein responsible for the deposits. Each type has a distinct cause, progression, and treatment approach.
AL Amyloidosis (Light Chain Amyloidosis)
AL amyloidosis, previously called primary amyloidosis, is the most common type affecting the heart. It develops when abnormal plasma cells in the bone marrow produce excess light chain proteins. These proteins misfold and deposit in organs, including the heart.
AL amyloidosis progresses rapidly and can severely damage multiple organs within months. It is closely linked to plasma cell disorders such as multiple myeloma. Treatment focuses on targeting the underlying bone marrow abnormality.
ATTR Amyloidosis (Transthyretin Amyloidosis)
ATTR amyloidosis involves a protein called transthyretin (TTR), which is produced mainly by the liver. This protein normally transports thyroid hormone and vitamin A. When transthyretin becomes unstable, it misfolds and deposits in the heart and other tissues.
ATTR amyloidosis has two forms. Wild-type ATTR (previously called senile systemic amyloidosis) occurs due to age-related protein instability, primarily affecting older men. Hereditary ATTR results from a genetic mutation in the TTR gene and can affect younger individuals.
Other Rarer Forms
Secondary amyloidosis caused by AA protein rarely affects the heart significantly. Certain inherited forms involving other proteins such as apolipoprotein A-I can occasionally cause cardiac involvement. These forms are uncommon but important to recognize in clinical practice.
Who Is at Risk?
Cardiac amyloidosis can affect a wide range of individuals, though certain groups carry a higher risk. Age is a significant factor, particularly for wild-type ATTR amyloidosis, which predominantly affects men over 65. This form is increasingly recognised as an underdiagnosed cause of heart failure in older adults.
Genetic and Ethnic Risk Factors
Hereditary ATTR amyloidosis affects people who carry specific mutations in the TTR gene. One particular mutation, Val122Ile (now renamed V122I), is present in approximately 3–4% of people of West African ancestry. This mutation significantly increases the risk of developing cardiac amyloidosis.
Other TTR mutations associated with cardiac disease are found in populations across Portugal, Sweden, and Japan. Genetic testing can identify these mutations before symptoms develop, enabling earlier monitoring and intervention.
Risk Linked to Underlying Conditions
People with plasma cell disorders such as multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS) carry a higher risk of AL amyloidosis. Those with a family history of amyloidosis should consider genetic counselling and regular cardiac screening.
Recognising the Symptoms
Cardiac amyloidosis often mimics common heart conditions, which makes early diagnosis challenging. Symptoms develop gradually and may be attributed to ageing or other diseases for extended periods.
Early Warning Signs
Breathlessness during physical activity is frequently the first symptom patients notice. Fatigue and reduced exercise tolerance are also common early complaints. These symptoms occur because the stiffened heart struggles to maintain adequate blood flow during exertion.
Swelling in the legs, ankles, or feet, known as peripheral oedema, often accompanies breathlessness. This occurs when fluid backs up due to impaired heart function. Some patients also experience abdominal swelling and weight gain from fluid accumulation.
Additional Cardiac Symptoms
Palpitations and irregular heartbeat, including atrial fibrillation, affect many people with cardiac amyloidosis. Dizziness and fainting episodes may occur due to low blood pressure or arrhythmias. Some patients experience angina-like chest pain or pressure, though this is less common.
Non-Cardiac Clues
Cardiac amyloidosis rarely occurs in isolation. Many patients also experience symptoms from amyloid deposits in other parts of the body. These include numbness or tingling in the hands, particularly consistent with carpal tunnel syndrome, which often precedes cardiac symptoms by years.
Autonomic neuropathy — affecting the nerves that control automatic body functions — can cause dizziness when standing, digestive problems, and difficulty regulating body temperature. Recognising these non-cardiac signs can significantly accelerate diagnosis.
How Doctors Diagnose Cardiac Amyloidosis
Diagnosing cardiac amyloidosis requires a combination of clinical evaluation, imaging studies, laboratory tests, and in some cases, tissue biopsy. No single test is sufficient alone.
Echocardiography and Cardiac MRI
Echocardiography, an ultrasound scan of the heart, is often the first imaging test performed. It can reveal a thickened, stiff heart muscle with a characteristic granular sparkling appearance. However, these features can be subtle, particularly in early disease.
Cardiac MRI provides more detailed information about the heart’s structure and function. It uses gadolinium contrast to detect a specific pattern of late gadolinium enhancement, which is highly characteristic of amyloid infiltration. Cardiac MRI helps assess the extent of disease and guides treatment planning.
Nuclear Imaging (Bone Scintigraphy)
Technetium-labelled bone scintigraphy has become a critical non-invasive test for ATTR cardiac amyloidosis. This nuclear imaging technique uses a radioactive tracer that binds selectively to transthyretin amyloid deposits in the heart. A strongly positive scan can confirm ATTR amyloidosis without the need for a biopsy.
This technique has transformed diagnostic accuracy in recent years, enabling earlier and more precise identification of ATTR amyloidosis. It does not reliably detect AL amyloidosis, making laboratory testing essential alongside imaging.
Blood and Urine Tests
Blood tests measuring serum free light chains and serum protein electrophoresis help identify AL amyloidosis by detecting abnormal plasma cell proteins. Elevated cardiac biomarkers such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) and troponin indicate cardiac stress and help gauge disease severity.
Urine protein electrophoresis may also reveal abnormal protein excretion. Together, these tests help distinguish AL from ATTR amyloidosis, which is critical because treatment approaches differ significantly.
Tissue Biopsy
When non-invasive tests are inconclusive, a tissue biopsy may be necessary to confirm amyloidosis. An abdominal fat pad biopsy is a minimally invasive procedure that detects systemic amyloid deposits in many patients. In some cases, a bone marrow biopsy or heart biopsy may be required for a definitive diagnosis.
Biopsy samples are stained with Congo red dye, which shows a characteristic apple-green birefringence under polarised light when amyloid is present.
Treatment Options for Cardiac Amyloidosis
Treatment strategies depend on the type of amyloidosis, the severity of cardiac involvement, and the patient’s overall health. Significant advances in therapy have transformed outcomes, especially for ATTR amyloidosis.
Treating AL Amyloidosis
Treatment for AL amyloidosis targets the underlying plasma cell disorder. Chemotherapy regimens, often including bortezomib and dexamethasone, aim to suppress abnormal plasma cell production and reduce light chain levels. High-dose chemotherapy followed by autologous stem cell transplantation offers deeper and more durable responses in eligible patients.
Achieving haematological remission slows or halts further amyloid deposition, allowing the heart to recover partially over time. Daratumumab-based regimens have shown remarkable efficacy in recent clinical trials.
Treating ATTR Amyloidosis
Several disease-modifying therapies are now available for ATTR amyloidosis. Tafamidis (Vyndaqel/Vyndamax) stabilises the transthyretin protein and prevents it from misfolding and forming amyloid deposits. The landmark ATTR-ACT trial demonstrated that tafamidis significantly reduces cardiovascular mortality and hospitalisations in patients with ATTR cardiomyopathy.
Gene-silencing therapies such as patisiran and inotersen reduce TTR protein production in the liver, lowering the supply of protein available to misfold. These treatments are particularly effective in hereditary ATTR amyloidosis. Newer agents including vutrisiran offer subcutaneous administration, improving convenience and compliance.
Managing Heart Failure Symptoms
Alongside disease-specific treatments, managing heart failure symptoms remains essential. Diuretics help reduce fluid overload and relieve breathlessness and oedema. Patients with cardiac amyloidosis require careful fluid management, as the stiffened heart is sensitive to both excess fluid and dehydration.
Standard heart failure medications such as beta-blockers, ACE inhibitors, and angiotensin receptor blockers must be used cautiously. These medications can cause problematic drops in blood pressure in amyloidosis patients. Specialist cardiology guidance is essential when adjusting cardiac medications.
Arrhythmia Management and Device Therapy
Atrial fibrillation is common in cardiac amyloidosis and increases the risk of stroke significantly. Anticoagulation therapy reduces stroke risk, though the choice of agent requires careful consideration of bleeding risk. Rate or rhythm control strategies help manage symptoms.
Some patients develop conduction abnormalities requiring a pacemaker. Implantable cardioverter-defibrillators (ICDs) may be considered in selected patients with life-threatening arrhythmias. Device therapy decisions should involve a multidisciplinary cardiology team.
Heart Transplantation
Heart transplantation remains an option for a carefully selected group of patients with severe AL amyloidosis. However, transplantation alone does not address the underlying plasma cell disorder, making combined heart and bone marrow transplantation necessary in some cases. Patient selection for transplantation requires extensive multidisciplinary evaluation.
Living With Cardiac Amyloidosis
A cardiac amyloidosis diagnosis is life-changing, but many patients can lead meaningful, active lives with appropriate treatment and support. Adapting to the disease requires both medical management and lifestyle adjustments.
Activity and Exercise
Moderate, low-intensity physical activity can be beneficial for many patients with cardiac amyloidosis. Gentle walking, yoga, and stretching help maintain fitness without overloading the heart. However, strenuous or high-intensity exercise should be avoided without specific medical clearance.
Dietary Considerations
Reducing dietary sodium (salt) intake helps prevent fluid retention and eases the heart’s workload. Patients taking diuretics must maintain adequate hydration while avoiding excess fluid. Consulting a registered dietitian provides personalised guidance aligned with cardiac and renal health.
Emotional and Psychological Support
Living with a serious cardiac condition affects mental health significantly. Anxiety, depression, and fear of disease progression are common emotional responses. Seeking support through counselling, psychotherapy, or patient support groups helps address these challenges constructively.
Connecting with organisations such as the Amyloidosis Research Consortium or national amyloidosis patient groups provides access to community, updated information, and specialist resources.
Prognosis and Outlook
The outlook for cardiac amyloidosis has improved substantially in recent years due to advances in diagnosis and treatment. However, prognosis varies widely based on amyloidosis type, extent of cardiac involvement, and timing of diagnosis.
Outlook for AL Amyloidosis
AL amyloidosis with significant cardiac involvement carries a more guarded prognosis compared to ATTR. Without treatment, median survival was historically less than one year after diagnosis. With modern chemotherapy regimens, many patients now achieve durable remissions and markedly improved survival.
Early diagnosis before severe cardiac damage occurs greatly improves outcomes. Biomarker staging systems using NT-proBNP and troponin levels help stratify prognosis and guide treatment intensity.
Outlook for ATTR Amyloidosis
Wild-type ATTR amyloidosis tends to progress more slowly than AL amyloidosis, and patients may survive for several years after diagnosis. Tafamidis therapy has demonstrated a significant survival benefit in randomised trials, making early initiation of treatment increasingly important.
Hereditary ATTR amyloidosis has variable progression depending on the specific TTR mutation involved. Some mutations carry a predominantly neurological phenotype, while others cause primarily cardiac disease. Genetic counselling assists affected individuals and their families in understanding disease trajectory and testing options.
Frequently Asked Questions
What causes cardiac amyloidosis?
Cardiac amyloidosis occurs when abnormal proteins misfold and accumulate as amyloid deposits within the heart muscle. The most common causes are abnormal plasma cell production (AL amyloidosis) and instability of the transthyretin protein due to ageing or genetic mutation (ATTR amyloidosis). Both processes lead to progressive stiffening and impaired heart function.
Is cardiac amyloidosis the same as heart failure?
Cardiac amyloidosis is not the same as ordinary heart failure, though it leads to heart failure as a complication. It is a specific infiltrative disease where protein deposits cause the heart to stiffen. Standard heart failure treatments may not be appropriate or effective for amyloidosis, making accurate diagnosis critical for proper management.
Can cardiac amyloidosis be cured?
There is currently no complete cure for cardiac amyloidosis, but effective treatments exist. AL amyloidosis can achieve deep remission with modern chemotherapy, halting further damage and allowing partial recovery. ATTR amyloidosis can be slowed significantly with tafamidis and gene-silencing therapies. Early diagnosis improves the chances of meaningful disease control.
How is ATTR amyloidosis different from AL amyloidosis?
ATTR amyloidosis involves the transthyretin protein produced by the liver and is often associated with ageing or genetic mutations. AL amyloidosis involves light chain proteins produced by abnormal plasma cells in the bone marrow, similar to those seen in myeloma. The two types require completely different treatment approaches, making accurate differentiation essential.
Is cardiac amyloidosis hereditary?
Some forms of cardiac amyloidosis are hereditary. Hereditary ATTR amyloidosis is caused by mutations in the TTR gene and can be passed from parent to child. AL amyloidosis is not directly inherited, though genetic predisposition to plasma cell disorders may play a role. Genetic testing and family counselling are recommended when hereditary ATTR is suspected.
Who should be screened for cardiac amyloidosis?
People with unexplained heart failure with preserved ejection fraction, particularly older men, should be evaluated for amyloidosis. Individuals with carpal tunnel syndrome followed by cardiac symptoms, bilateral trigger finger, or spinal stenosis warrant screening. Those with a family history of TTR mutations or people of West African ancestry with heart failure should also consider specialist assessment.
Conclusion
Cardiac amyloidosis is no longer a rare diagnosis reserved for specialist textbooks. Growing awareness, improved imaging techniques, and powerful new therapies have transformed how clinicians and patients approach this once-overlooked condition. The heart deserves protection, and recognising the warning signs early makes all the difference.
If you or someone you know experiences unexplained breathlessness, fatigue, or a thickened heart on imaging, ask about amyloidosis. Early diagnosis opens the door to treatments that can genuinely slow the disease and extend quality of life. Awareness is the first, most powerful medicine.
References
- The fundamental problem in Restrictive Cardiomyopathy is myocardial stiffness.
- Vascular Dementia is cognitive impairment resulting from reduced blood flow to the brain caused by cerebrovascular disease.
- The heart is a muscle that contracts to work as a pump.Â
Disclaimer:
This article is intended for general informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis, treatment, or health-related decisions.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
